Sontra Medical gets U.S. patent for non-invasive body fluid sampling, analysis

By Elaine Rigoli

Tampa, Fla., July 20 - Sontra Medical Corp. said it received a U.S. patent describing the technology for transdermal continuous glucose monitoring that details both the method and system to enhance the permeability of skin, ultimately facilitating the continuous detection of a body analyte, such as blood glucose.

"This patent further strengthens the intellectual property portfolio surrounding Sontra's non-invasive diagnostics, and is central in transdermal and continuous glucose monitoring technology," vice president of research and development Scott Kellogg said in a news release.

Sontra's continuous non-invasive glucose monitoring technology measures glucose diffusing through ultrasonically permeated skin for 24 hours, the release said.

Franklin, Mass.-based Sontra Medical is a drug-delivery and diagnostics company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.